NutriBand Inc. (NTRB)
Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Manufacturing · CIK 1676047 · fiscal year ends in Jan
Closing price $6.23 on 30 Oct 2026; 52-week range $2.81 to $8.99.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $1.6M
- Revenue growth
- -37.3%
- Net income, last twelve months
- -$7.0M
- Gross margin
- 33.1%
- Operating margin
- -435.6%
- Net margin
- -430.4%
- Return on equity
- -130.7%
- Market value
- $75.7M
- Cash
- $3.4M
- Debt
- $25.1K
- Debt to equity
- 0.00
- Shares outstanding
- 12.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 31 Jan 2026 | $2.0M | -$8.3M | -$8.2M | -$2.58 | -$5.1M | 10-K filed 29 Apr 2026 |
| FY2025 | 31 Jan 2025 | $2.1M | -$10.3M | -$10.5M | -$0.99 | -$4.7M | 10-K filed 28 Apr 2025 |
| FY2024 | 31 Jan 2024 | $2.1M | -$4.9M | -$5.5M | -$0.69 | -$3.6M | 10-K filed 1 May 2024 |
| FY2023 | 31 Jan 2023 | $2.1M | -$4.5M | -$4.5M | -$0.53 | -$3.1M | 10-K filed 26 Apr 2023 |
| FY2022 | 31 Jan 2022 | $1.4M | -$6.1M | -$6.2M | -$0.80 | -$2.9M | 10-K filed 29 Apr 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2027 | 31 Jul 2026 | $437.5K | -$880.6K | -$0.07 |
| Q1 FY2027 | 30 Apr 2026 | $433.4K | -$1.2M | -$0.10 |
| Q4 FY2026 | 31 Jan 2026 | $400.7K | -$968.1K | -$0.02 |
| Q3 FY2026 | 31 Oct 2025 | $346.1K | -$3.9M | -$0.32 |
| Q2 FY2026 | 31 Jul 2025 | $622.5K | -$2.0M | -$2.12 |
| Q1 FY2026 | 30 Apr 2025 | $667.4K | -$1.4M | -$0.12 |
| Q4 FY2025 | 31 Jan 2025 | $642.4K | -$5.5M | -$0.51 |
| Q3 FY2025 | 31 Oct 2024 | $645.8K | -$1.4M | -$0.12 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2026
| Segment | Revenue | Share |
|---|---|---|
| United States | $2.0M | 99.6% |
| Foreign | $7.6K | 0.4% |
Company events
The newest 8-K filings of 79 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 23 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 22 Jun 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 7 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
| 3 Feb 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 30 Dec 2025 | 8-K | Investor update | 7.01, 9.01 |
| 28 Oct 2025 | 8-K | Investor update | 7.01, 9.01 |
| 3 Sep 2025 | 8-K | Investor update | 7.01, 9.01 |
| 7 Aug 2025 | 8-K | Share sale, Bylaws or fiscal year change | 3.02, 5.03, 9.01 |
| 16 Jul 2025 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 9 Apr 2025 | 8-K | Investor update | 7.01, 9.01 |
| 13 Feb 2025 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 209 held.
| Filed | Form | Period |
|---|---|---|
| 30 Sep 2026 | 25-NSE | – |
| 23 Sep 2026 | 8-K | 21 Sep 2026 |
| 4 Sep 2026 | 10-Q | 31 Jul 2026 |
| 22 Jun 2026 | 8-K | 1 Jun 2026 |
| 11 Jun 2026 | 10-Q | 30 Apr 2026 |
| 18 May 2026 | 10-K/A | 31 Jan 2026 |
| 29 Apr 2026 | 10-K | 31 Jan 2026 |
| 7 Apr 2026 | 8-K | 30 Mar 2026 |
| 13 Feb 2026 | 8-K | 13 Feb 2026 |
| 3 Feb 2026 | 8-K | 24 Jan 2026 |
| 30 Dec 2025 | 8-K | 30 Dec 2025 |
| 19 Dec 2025 | DEF 14A | 24 Jan 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 Sep 2026 | Gareth Sheridan | 13D amended | 14.2% | 1.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 157.8K | +2.84% | 3.55 |
| 30 Sep 2026 | 153.4K | -13.7% | 1 |
| 15 Sep 2026 | 177.8K | +3.08% | 2.18 |
| 31 Aug 2026 | 172.5K | +1.42% | 3.76 |
| 14 Aug 2026 | 170.1K | +0.65% | 30.1 |
| 31 Jul 2026 | 169.0K | +7.7% | 17.85 |
| 15 Jul 2026 | 156.9K | +2.53% | 11.36 |
| 30 Jun 2026 | 153.1K | -14.33% | 9.38 |
Funds that hold it
From each fund's latest Form 13F.
18 funds held it at 30 Jun 2026: 5 added and 4 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Vanguard Capital Management LLC | 174,927 | $558.0K | 0 |
| Geode Capital Management, LLC | 62,494 | $199.4K | -7,559 |
| Vanguard Fiduciary Trust Co. | 25,111 | $80.1K | 0 |
| State Street Corp. | 24,966 | $79.6K | 0 |
| BFC Planning, Inc. | 19,000 | $60.6K | +2,500 |
| Citadel Advisors LLC | 18,996 | $60.6K | +18,996 |
| Northern Trust Corp. | 11,570 | $36.9K | -2,375 |
| Haven Private, LLC | 11,366 | $36.3K | 0 |
| BlackRock, Inc. | 10,662 | $34.0K | +1,121 |
| Osaic Holdings, Inc. | 3,684 | $11.8K | -1,167 |
Peers
Companies in the same industry.
- Intuitive Surgical Inc. (ISRG): revenue $11.6B, market value $149.8B
- Edwards Lifesciences Corp. (EW): revenue $6.5B, market value $53.1B
- Steris plc (STE): revenue $6.0B, market value $22.1B
- Zimmer Biomet Holdings, Inc. (ZBH): revenue $8.5B, market value $18.0B
- Smith & Nephew plc (SNN): revenue $6.2B, market value $13.0B
- Align Technology Inc. (ALGN): revenue $4.1B, market value $10.7B
- MSA Safety Inc. (MSA): revenue $1.9B, market value $6.9B
- Establishment Labs Holdings Inc. (ESTA): revenue $245.8M, market value $1.9B
- Cadre Holdings, Inc. (CDRE): revenue $685.6M, market value $1.3B
- Enovis Corp. (ENOV): revenue $2.3B, market value $1.1B